Tech Company Financing Transactions

PhaseBio Pharmaceuticals Funding Round

On 9/6/2018, PhaseBio Pharmaceuticals announced $34 million in Series D financing from AstraZeneca, Cormorant Asset Management and Fletcher Spaght Ventures.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

1 Great Valley Pkwy. 30
Malvern, PA 19355
USA

Phone

(610) 981-6500

Website

www.phasebio.com

Email Address

Not Recorded

Overview

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), located in Malvern, PA, is a development stage, privately held protein engineering company focused on developing the next generation of biopharmaceuticals.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Jonathan Mow

        

Chief Financial Officer

John Sharp

        

Chief Medical Officer

John Lee

        

VP - Bus. Development

Susan Arnold

        

VP - Bus. Development

Michael York

        

VP - R & D

James Ballance

        

Browse more venture capital transactions:

Prev: 9/6/2018: Arkose Labs venture capital transaction
Next: 9/6/2018: Cricket Health venture capital transaction

Share this article

About Database of VC Transactions

We do our best to document tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary